Go Pro
→ This tiny piece of glass could be bigger than GPUs (From Brownstone Research) (Ad)tc pixel Free CALC Stock Alerts

CalciMedica (CALC) Financials

CalciMedica logo
$0.70 -0.06 (-7.45%)
Closing price 07/27/2026 04:00 PM Eastern
Extended Trading
$0.72 +0.02 (+3.09%)
As of 07/27/2026 06:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for CalciMedica

Annual Income Statements for CalciMedica

This table shows CalciMedica's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -44 -35 -36 -9.14 -34 -14 -30
Consolidated Net Income / (Loss)		 -37 -28 -36 -7.82 -34 -14 -30
Net Income / (Loss) Continuing Operations		 -37 -30 -36 -7.82 -34 -14 -30
Total Pre-Tax Income 		-37 -30 -36 -7.82 -34 -14 -30
Total Operating Income		 -38 -30 -36 -14 -38 -24 -23
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 38 30 36 14 38 24 23
Selling, General & Admin Expense		 6.92 8.87 17 5.84 22 9.73 7.89
Research & Development Expense		 31 21 19 8.35 16 14 15
Total Other Income / (Expense), net		 0.39 0.14 0.13 6.37 3.72 11 -6.44
Interest Expense		 - - - 0.13 - 0.00 1.42
Interest & Investment Income		 0.39 0.14 0.13 - - 1.01 0.71
Other Income / (Expense), net		 - - - 6.50 3.72 9.49 -5.73
Basic Earnings per Share		 ($33.41) ($5.25) ($1.69) ($111.16) ($7.66) ($1.22) ($1.97)
Weighted Average Basic Shares Outstanding		 1.32M 6.62M 21.20M 82.25K 4.49M 11.25M 15.01M
Diluted Earnings per Share		 ($33.41) ($5.25) ($1.69) ($111.16) ($7.66) ($1.22) ($1.97)
Weighted Average Diluted Shares Outstanding		 1.32M 6.62M 21.20M 82.25K 4.49M 11.25M 15.01M
Weighted Average Basic & Diluted Shares Outstanding		 1.32M 6.62M 21.20M 22.00M 10.74M 13.48M 15.74M

Quarterly Income Statements for CalciMedica

This table shows CalciMedica's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -4.62 -4.15 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Consolidated Net Income / (Loss)		 -4.62 -4.15 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Net Income / (Loss) Continuing Operations		 -4.62 -4.03 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Total Pre-Tax Income 		-4.62 -4.03 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Total Operating Income		 -4.83 -4.32 -5.77 -6.53 -5.74 -6.17 -6.50 -6.62 -5.62 -4.39 -5.61
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 4.83 4.32 5.77 6.53 5.74 6.17 6.50 6.62 5.62 4.39 5.61
Selling, General & Admin Expense		 2.06 1.54 2.82 2.37 2.19 2.34 2.27 2.57 1.77 1.28 2.13
Research & Development Expense		 2.77 2.78 2.94 4.16 3.55 3.83 4.22 4.05 3.85 3.11 3.49
Total Other Income / (Expense), net		 0.21 0.29 5.90 2.58 0.12 1.91 1.46 0.67 -2.19 -6.38 11
Interest Expense		 - - 0.00 0.00 0.00 - 0.45 0.32 0.33 0.33 0.32
Interest & Investment Income		 - - 0.31 0.28 0.22 0.21 0.20 0.22 0.14 0.15 0.11
Other Income / (Expense), net		 0.21 0.29 5.59 2.30 -0.10 1.70 1.70 0.77 -2.00 -6.20 11
Basic Earnings per Share		 ($0.82) $17.70 $0.01 ($0.36) ($0.50) ($0.37) ($0.36) ($0.40) ($0.52) ($0.69) $0.31
Weighted Average Basic Shares Outstanding		 5.67M 4.49M 9.75M 11.13M 11.13M 11.25M 14.12M 15.00M 15.08M 15.01M 15.82M
Diluted Earnings per Share		 ($0.82) $17.70 $0.01 ($0.36) ($0.50) ($0.37) ($0.36) ($0.40) ($0.52) ($0.69) $0.30
Weighted Average Diluted Shares Outstanding		 5.67M 4.49M 10.05M 11.13M 11.13M 11.25M 14.12M 15.00M 15.08M 15.01M 16.33M
Weighted Average Basic & Diluted Shares Outstanding		 5.68M 10.74M 10.75M 10.75M 13.48M 13.48M 13.97M 13.97M - 15.74M 15.80M

Annual Cash Flow Statements for CalciMedica

This table details how cash moves in and out of CalciMedica's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.04 18 -20 -3.29 4.05 2.41 3.59
Net Cash From Operating Activities		 -31 -32 -32 -12 -26 -21 -21
Net Cash From Continuing Operating Activities		 -31 -32 -32 -12 -26 -21 -21
Net Income / (Loss) Continuing Operations		 -37 -28 -36 -7.82 -34 -14 -30
Consolidated Net Income / (Loss)		 -37 -28 -36 -7.82 -34 -14 -30
Depreciation Expense		 0.30 0.40 0.52 0.05 0.06 0.06 0.05
Amortization Expense		 -0.07 0.00 0.06 0.00 -0.15 -0.61 -0.35
Non-Cash Adjustments To Reconcile Net Income		 0.67 -0.37 5.38 -4.59 8.98 -6.40 9.31
Changes in Operating Assets and Liabilities, net		 4.92 -4.56 -1.63 0.61 -0.27 -0.50 -0.62
Net Cash From Investing Activities		 -21 -43 11 -0.00 8.88 -4.42 9.55
Net Cash From Continuing Investing Activities		 -21 -43 11 -0.00 8.88 -4.42 9.55
Purchase of Property, Plant & Equipment		 -0.61 -1.02 -0.49 -0.00 -0.08 -0.01 -0.03
Purchase of Investments		 -23 -62 -95 0.00 -6.12 -29 -16
Sale and/or Maturity of Investments		 2.50 20 106 0.00 15 25 25
Net Cash From Financing Activities		 55 92 0.70 8.48 21 28 15
Net Cash From Continuing Financing Activities		 55 92 0.70 8.48 21 28 15
Issuance of Debt		 - - - - 0.00 0.00 9.66
Issuance of Common Equity		 0.05 96 - 0.02 11 28 5.52
Other Financing Activities, net		 0.13 0.08 0.70 0.00 15 0.02 0.03
Cash Interest Paid		 - - - - - 0.00 1.09

Quarterly Cash Flow Statements for CalciMedica

This table details how cash moves in and out of CalciMedica's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.44 -6.11 1.23 -1.70 4.10 -1.22 4.62 -6.64 -0.45 6.05 -3.36
Net Cash From Operating Activities		 -4.57 -3.61 -4.72 -6.79 -4.67 -4.97 -4.88 -6.67 -4.78 -4.85 -4.86
Net Cash From Continuing Operating Activities		 -4.57 -3.61 -4.72 -6.79 -4.67 -4.97 -4.88 -6.67 -4.78 -4.85 -4.86
Net Income / (Loss) Continuing Operations		 -4.62 -4.15 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Consolidated Net Income / (Loss)		 -4.62 -4.15 0.13 -3.95 -5.62 -4.26 -5.04 -5.96 -7.80 -11 4.98
Depreciation Expense		 0.01 0.02 0.02 0.01 0.02 0.01 0.02 0.01 0.01 0.01 0.01
Amortization Expense		 -0.01 -0.08 -0.16 -0.22 -0.11 -0.12 -0.11 -0.11 -0.09 -0.04 -0.00
Non-Cash Adjustments To Reconcile Net Income		 0.48 -0.03 -4.40 -1.81 0.88 -1.07 -0.82 0.68 2.63 6.82 -10
Changes in Operating Assets and Liabilities, net		 -0.44 0.63 -0.30 -0.82 0.17 0.46 1.07 -1.29 0.48 -0.88 0.40
Net Cash From Investing Activities		 -2.94 -2.68 -13 5.10 8.75 -5.17 -1.24 0.13 3.51 7.15 1.50
Net Cash From Continuing Investing Activities		 -2.94 -2.68 -13 5.10 8.75 -5.17 -1.24 0.13 3.51 7.15 1.50
Purchase of Property, Plant & Equipment		 - - 0.00 - -0.01 -0.00 -0.01 -0.01 -0.01 -0.01 0.00
Purchase of Investments		 -2.94 -3.18 -18 - -0.98 -10 -6.63 -7.31 -1.48 -0.50 0.00
Sale and/or Maturity of Investments		 - 0.50 4.75 5.10 9.74 5.00 5.40 7.45 5.00 7.65 1.50
Net Cash From Financing Activities		 0.07 0.18 19 -0.01 0.02 8.92 11 -0.10 0.82 3.75 0.00
Net Cash From Continuing Financing Activities		 0.07 0.18 19 -0.01 0.02 8.92 11 -0.10 0.79 3.78 0.00
Issuance of Debt		 - - 0.00 - - - 9.77 -0.10 - - 0.00
Issuance of Common Equity		 0.07 0.17 19 -0.01 - 8.92 0.98 - 0.79 3.75 0.00
Other Financing Activities, net		 - - - - 0.02 - 0.00 - 0.03 - 0.00
Cash Interest Paid		 - - - - - - 0.00 - - - 0.32

Annual Balance Sheets for CalciMedica

This table presents CalciMedica's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 41 102 69 3.35 12 20 14
Total Current Assets		 36 99 67 1.73 12 20 14
Cash & Equivalents		 16 33 13 1.33 5.53 7.94 12
Short-Term Investments		 20 62 50 0.00 5.71 11 1.50
Prepaid Expenses		 0.32 4.21 3.41 0.25 0.37 1.00 0.46
Other Current Assets		 - - - - - 0.00 0.05
Plant, Property, & Equipment, net		 1.98 1.95 1.98 0.15 0.17 0.12 0.05
Total Noncurrent Assets		 2.41 0.61 0.03 1.47 0.41 0.01 0.01
Other Noncurrent Operating Assets		 2.41 0.61 0.03 1.47 0.41 0.01 0.01
Total Liabilities & Shareholders' Equity		 41 102 69 3.35 12 20 14
Total Liabilities		 12 7.01 4.07 13 4.03 5.38 20
Total Current Liabilities		 12 7.00 4.06 4.78 4.03 3.68 3.78
Accounts Payable		 4.64 2.51 0.53 2.87 1.42 2.00 1.16
Accrued Expenses		 2.33 1.36 0.30 1.72 2.61 1.69 1.37
Other Current Liabilities		 5.28 3.13 3.23 0.20 - 0.00 1.25
Total Noncurrent Liabilities		 0.00 0.01 0.01 7.80 0.00 1.70 16
Long-Term Debt		 - - - 5.16 - 0.00 8.45
Other Noncurrent Operating Liabilities		 - - - 2.65 0.00 1.70 8.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -103 95 65 -71 8.16 14 -6.64
Total Preferred & Common Equity		 -103 95 65 -71 8.16 14 -6.64
Preferred Stock		 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Common Equity		 -103 95 65 -71 8.16 14 -6.64
Common Stock		 2.88 228 234 40 154 174 183
Retained Earnings		 -106 -133 -169 -112 -146 -160 -189

Quarterly Balance Sheets for CalciMedica

This table presents CalciMedica's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 16 27 21 16 25 19 15 8.61
Total Current Assets		 15 27 20 16 25 19 15 8.56
Cash & Equivalents		 12 6.76 5.06 9.15 13 5.92 5.47 8.16
Short-Term Investments		 2.95 19 14 5.45 12 12 8.61 0.00
Prepaid Expenses		 0.68 0.89 1.31 1.08 0.59 1.01 0.77 0.34
Other Current Assets		 - - - - - - - 0.05
Plant, Property, & Equipment, net		 0.19 0.15 0.14 0.13 0.12 0.11 0.05 0.04
Total Noncurrent Assets		 0.39 0.38 0.47 0.40 0.01 0.01 0.01 0.01
Other Noncurrent Operating Assets		 0.39 0.38 0.47 0.40 0.01 0.01 0.01 0.01
Total Liabilities & Shareholders' Equity		 16 27 21 16 25 19 15 8.61
Total Liabilities		 3.69 9.89 7.21 7.18 14 13 15 9.71
Total Current Liabilities		 3.69 4.29 3.91 3.78 4.46 3.48 3.68 5.31
Accounts Payable		 1.42 1.54 2.14 1.54 2.02 1.91 1.13 1.68
Accrued Expenses		 2.27 2.75 1.77 2.25 2.44 1.57 2.55 1.14
Other Current Liabilities		 0.00 - - - - - - 2.50
Total Noncurrent Liabilities		 0.00 5.60 3.30 3.40 10 9.50 12 4.40
Long-Term Debt		 0.00 - - - - - - 4.20
Other Noncurrent Operating Liabilities		 0.00 5.60 3.30 3.40 10 9.50 12 0.20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 12 17 14 9.03 11 6.10 -0.27 -1.10
Total Preferred & Common Equity		 12 17 14 9.03 11 6.10 -0.27 -1.10
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 12 17 14 9.03 11 6.10 -0.27 -1.10
Common Stock		 154 163 164 165 176 177 178 183
Retained Earnings		 -142 -146 -150 -156 -165 -171 -179 -184

Annual Metrics And Ratios for CalciMedica

This table displays calculated financial ratios and metrics derived from CalciMedica's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 20,979,265.00 21,319,635.00 21,562,523.00 5,684,873.00 13,481,917.00 13,972,177.00
DEI Adjusted Shares Outstanding		 0.00 1,498,519.00 1,522,831.00 1,540,180.00 5,684,873.00 13,481,917.00 13,972,177.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -23.17 -23.52 -5.94 -6.04 -1.02 -2.12
Growth Metrics		 - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% 21.01% -20.16% 78.40% -350.84% 55.68% -90.99%
EBIT Growth		 0.00% 20.45% -20.50% 78.60% -346.66% 57.17% -96.09%
NOPAT Growth		 0.00% 20.45% -20.50% 60.52% -168.27% 36.43% 4.47%
Net Income Growth		 0.00% 25.67% -30.11% 78.16% -339.12% 60.12% -115.78%
EPS Growth		 0.00% 84.29% 67.81% -6,477.51% 93.11% 84.07% -61.48%
Operating Cash Flow Growth		 0.00% -2.72% 1.76% 62.68% -118.85% 17.82% -0.15%
Free Cash Flow Firm Growth		 0.00% 0.00% 5.04% 88.68% -861.14% 45.87% 41.41%
Invested Capital Growth		 0.00% 96.73% 647.77% -510.35% 44.51% -38.23% -163.14%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 1.30% 61.08% -19.77% -3.24% -31.95%
EBIT Q/Q Growth		 0.00% 0.00% 1.30% 61.13% -19.51% -3.10% -32.81%
NOPAT Q/Q Growth		 0.00% 0.00% 1.30% 28.28% -3.29% -8.29% 7.17%
Net Income Q/Q Growth		 0.00% 0.00% 1.31% 56.33% -19.32% -0.82% -28.20%
EPS Q/Q Growth		 0.00% 0.00% -118.00% 2.60% 66.40% -107.24% -19.39%
Operating Cash Flow Q/Q Growth		 0.00% 0.32% 2.53% 29.27% 1.82% -6.87% 0.56%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 75.25% -14.67% -26.07% -6.70%
Invested Capital Q/Q Growth		 0.00% 0.00% 423.68% -173.77% -26.69% 23.58% 21.91%
Profitability Metrics		 - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.81% 92.73% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.95% 99.52% 99.65% 101.72% 100.00% 93.11% 102.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -130.37% -44.70% -44.83% -28.05% 6,386.06% -121.42% -761.02%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,978.04% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 472.46% 2.96% -44.83% 3.16% 374,777.41% -121.42% -761.02%
Return on Equity Simple (ROE_SIMPLE)		 35.97% -29.05% -55.09% 10.97% -421.20% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 -21 -25 -9.94 -27 -17 -16
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -30.00% -10.15% -13.43% 7.04% -203.90% 21.69% -115.15%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -326.74% -117.58% -894.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -38 -30 -36 -7.69 -34 -15 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 -29 -35 -7.64 -34 -15 -29
Valuation Ratios		 - - - - - - -
Price to Book Value (P/BV)		 0.00 6.42 0.60 0.00 1.99 3.31 0.00
Price to Tangible Book Value (P/TBV)		 0.00 6.42 0.60 0.00 1.99 3.31 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - -
Debt to Equity		 0.00 0.00 0.00 -0.56 0.00 0.00 -1.27
Long-Term Debt to Equity		 0.00 0.00 0.00 -0.56 0.00 0.00 -1.27
Financial Leverage		 -1.27 -1.06 -0.99 -1.08 7.02 -1.33 -2.99
Leverage Ratio		 1.43 1.16 1.07 1.30 -14.44 1.42 4.30
Compound Leverage Factor		 1.42 1.15 1.07 1.32 -14.44 1.32 4.40
Debt to Total Capital		 0.00% 0.00% 0.00% -126.52% 0.00% 0.00% 467.11%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% -126.52% 0.00% 0.00% 467.11%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 462.40% 0.00% 0.00% -1,522.84% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -362.40% 100.00% 100.00% 1,749.36% 100.00% 100.00% -367.11%
Debt to EBITDA		 0.00 0.00 0.00 -0.68 0.00 0.00 -0.29
Net Debt to EBITDA		 0.00 0.00 0.00 -0.48 0.00 0.00 0.16
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.68 0.00 0.00 -0.29
Debt to NOPAT		 0.00 0.00 0.00 -0.52 0.00 0.00 -0.52
Net Debt to NOPAT		 0.00 0.00 0.00 -0.37 0.00 0.00 0.28
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.52 0.00 0.00 -0.52
Altman Z-Score		 -1.57 50.41 1.71 -54.86 -22.92 -7.47 -22.92
Noncontrolling Interest Sharing Ratio		 462.40% 106.63% 0.00% 111.26% -5,768.68% 0.00% 0.00%
Liquidity Ratios		 - - - - - - -
Current Ratio		 2.96 14.18 16.53 0.36 2.88 5.34 3.58
Quick Ratio		 2.93 13.58 15.69 0.28 2.79 5.07 3.44
Cash Flow Metrics		 - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -28 -27 -3.03 -29 -16 -9.24
Operating Cash Flow to CapEx		 -5,159.50% -3,134.31% -6,454.92% -293,925.00% -32,987.18% -264,325.00% -75,635.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -22.96 0.00 0.00 -6.50
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -89.07 0.00 0.00 -14.89
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -89.10 0.00 0.00 -14.91
Efficiency Ratios		 - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - -
Invested Capital		 -7.55 -0.25 1.35 -5.55 -3.08 -4.26 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 7.30 1.60 -6.91 2.47 -1.18 -6.95
Enterprise Value (EV)		 185 514 -25 77 5.02 29 88
Market Capitalization		 90 609 39 11 16 48 92
Book Value per Share		 ($78.00) $4.52 $3.05 ($3.31) $1.43 $1.07 ($0.44)
Tangible Book Value per Share		 ($78.00) $4.52 $3.05 ($3.31) $1.43 $1.07 ($0.44)
Total Capital		 28 95 65 -4.08 8.16 14 1.81
Total Debt		 0.00 0.00 0.00 5.16 0.00 0.00 8.45
Total Long-Term Debt		 0.00 0.00 0.00 5.16 0.00 0.00 8.45
Net Debt		 -36 -95 -64 3.68 -11 -19 -4.57
Capital Expenditures (CapEx)		 0.61 1.02 0.49 0.00 0.08 0.01 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -2.79 -0.65 -4.53 -3.66 -2.69 -3.27
Debt-free Net Working Capital (DFNWC)		 24 92 63 -3.05 7.58 16 9.75
Net Working Capital (NWC)		 24 92 63 -3.05 7.58 16 9.75
Net Nonoperating Expense (NNE)		 11 6.65 11 -2.11 7.70 -3.24 13
Net Nonoperating Obligations (NNO)		 -36 -95 -64 3.68 -11 -19 -4.57
Total Depreciation and Amortization (D&A)		 0.24 0.40 0.58 0.05 -0.09 -0.55 -0.30
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($73.50) ($23.66) ($23.24) ($7.66) ($1.22) ($1.97)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 1.50M 1.53M 1.53M 4.49M 11.25M 15.01M
Adjusted Diluted Earnings per Share		 $0.00 ($73.50) ($23.66) ($23.24) ($7.66) ($1.22) ($1.97)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 1.50M 1.53M 1.53M 4.49M 11.25M 15.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($73.50) ($23.66) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 472.75K 1.51M 1.57M 10.74M 13.48M 15.74M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 -21 -25 -9.94 -27 -17 -16
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -58.27 0.00 0.00 -20.29
NOPAT to Interest Expense		 0.00 0.00 0.00 -75.27 0.00 0.00 -11.38
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -58.30 0.00 0.00 -20.31
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -75.30 0.00 0.00 -11.40
Payout Ratios		 - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% -13.23% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -15.11% 0.00% 0.00% -13.23% 0.00% 0.00%

Quarterly Metrics And Ratios for CalciMedica

This table displays calculated financial ratios and metrics derived from CalciMedica's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 5,661,933.00 5,684,873.00 10,740,115.00 10,749,065.00 10,750,156.00 13,481,917.00 13,481,917.00 13,971,990.00 13,972,177.00 13,972,177.00 15,743,916.00
DEI Adjusted Shares Outstanding		 5,661,933.00 5,684,873.00 10,740,115.00 10,749,065.00 10,750,156.00 13,481,917.00 13,481,917.00 13,971,990.00 13,972,177.00 13,972,177.00 15,743,916.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.82 -0.73 0.01 -0.37 -0.52 -0.32 -0.37 -0.43 -0.56 -0.77 0.32
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -79.63% -357.39% 98.32% 30.11% -28.59% -11.70% -1,404.00% -34.22% -29.72% -132.16% 206.22%
EBIT Growth		 -78.96% -355.39% 99.09% 32.92% -26.35% -10.97% -2,610.17% -38.38% -30.53% -136.72% 208.17%
NOPAT Growth		 -46.99% 2.63% 63.12% 0.82% -18.68% -42.90% 21.14% -1.41% 2.06% 28.95% -23.38%
Net Income Growth		 -78.96% -392.59% 100.67% 37.28% -21.63% -2.70% -3,978.46% -50.63% -38.91% -152.70% 198.69%
EPS Growth		 97.36% 591.41% 100.04% 67.57% 39.02% -102.09% -3,700.00% -11.11% -4.00% -86.49% 183.33%
Operating Cash Flow Growth		 -150.33% 11.67% 11.95% 44.29% -2.10% -37.65% -3.46% 1.80% -2.38% 2.41% 0.45%
Free Cash Flow Firm Growth		 -330.75% -244.59% -275.03% 22.17% 70.66% 42.81% 107.69% 189.97% 654.38% 223.42% -2,066.67%
Invested Capital Growth		 -19.92% 44.51% 30.31% -85.09% -129.15% -38.23% -62.32% -123.70% -157.53% -163.14% 63.11%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 27.27% 11.23% 92.06% -1,264.00% -33.81% 22.89% -6.86% -21.73% -29.33% -38.00% 148.89%
EBIT Q/Q Growth		 26.73% 12.75% 95.61% -2,289.27% -38.00% 23.37% -7.27% -21.99% -30.18% -38.96% 149.02%
NOPAT Q/Q Growth		 26.58% 10.64% -90.75% 20.75% 12.15% -7.60% -5.27% -1.91% 15.15% 21.95% -82.80%
Net Income Q/Q Growth		 26.73% 10.24% 103.14% -3,141.54% -42.08% 24.21% -18.41% -18.13% -31.03% -37.88% 146.25%
EPS Q/Q Growth		 26.13% 2,258.54% -99.94% -3,700.00% -38.89% 26.00% 2.70% -11.11% -30.00% -32.69% 143.48%
Operating Cash Flow Q/Q Growth		 62.51% 20.98% -30.54% -44.05% 31.29% -6.54% 1.89% -36.74% 28.37% -1.55% -0.08%
Free Cash Flow Firm Q/Q Growth		 -8.64% -84.43% -71.94% 77.41% 59.04% -259.46% 123.11% 164.47% 152.38% -19.97% -468.18%
Invested Capital Q/Q Growth		 15.05% -26.69% -174.68% 37.39% -5.17% 23.58% -222.54% 13.71% -21.07% 21.91% 54.78%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 102.88% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% -73.45% 93.50% 96.26% 95.21% 105.11% 101.78% 102.44% 101.64% 95.90%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -107.12% 6,386.06% -76.09% -83.76% -128.26% -121.42% -134.15% -209.36% -526.36% -761.02% -399.51%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -107.12% 374,777.41% -76.09% -83.76% -128.26% -121.42% -134.15% -209.36% -526.36% -761.02% -399.51%
Return on Equity Simple (ROE_SIMPLE)		 -236.81% 0.00% -86.62% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.38 -3.02 -5.77 -4.57 -4.02 -4.32 -4.55 -4.63 -3.93 -3.07 -5.61
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.25% -29.71% 19.70% 3.22% -10.98% 0.42% -1.96% -7.12% -26.99% -66.20% 74.06%
Return On Investment Capital (ROIC_SIMPLE)		 - -37.06% -33.44% -33.03% -44.47% -29.98% -41.77% -75.94% 1,467.39% -169.68% -181.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.62 -4.03 -0.18 -4.23 -5.84 -4.47 -4.80 -5.85 -7.62 -11 5.19
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.61 -4.10 -0.33 -4.43 -5.93 -4.57 -4.89 -5.95 -7.70 -11 5.19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.24 1.99 2.59 3.08 5.27 3.31 2.37 3.66 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 1.24 1.99 2.59 3.08 5.27 3.31 2.37 3.66 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.27 -3.80
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.27 -3.80
Financial Leverage		 -1.08 7.02 -1.52 -1.27 -1.38 -1.33 -1.79 -1.86 -3.27 -2.99 -2.92
Leverage Ratio		 1.14 -14.44 1.57 1.37 1.51 1.42 1.87 2.01 3.55 4.30 3.47
Compound Leverage Factor		 1.14 -14.44 -1.16 1.28 1.46 1.35 1.96 2.05 3.64 4.37 3.33
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 467.11% 135.66%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 467.11% 135.66%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -367.11% -35.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.29 -0.22
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16 0.21
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.29 -0.22
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.52 -0.27
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.28 0.25
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.52 -0.27
Altman Z-Score		 -10.17 -14.71 -3.85 -6.15 -9.76 -5.76 -7.68 -11.53 -15.85 -18.48 -27.01
Noncontrolling Interest Sharing Ratio		 0.00% -5,768.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.14 2.88 6.21 5.22 4.15 5.34 5.66 5.45 4.04 3.58 1.61
Quick Ratio		 3.96 2.79 6.00 4.89 3.86 5.07 5.52 5.16 3.83 3.44 1.54
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.98 -5.49 -9.45 -2.13 -0.87 -3.14 0.73 1.92 4.85 3.88 -14
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% -77,783.33% -248,600.00% -54,200.00% -133,400.00% -59,725.00% -80,866.67% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 1.62 5.93 14.87 11.93 -44.76
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.91 -20.59 -14.66 -14.93 -15.22
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.93 -20.60 -14.68 -14.95 -15.22
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.43 -3.08 -8.46 -5.30 -5.57 -4.26 -14 -12 -14 -11 -5.07
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.40 2.47 3.68 -2.44 -3.14 -1.18 -5.27 -6.56 -8.78 -6.95 8.67
Enterprise Value (EV)		 0.47 5.02 19 23 33 29 1.13 4.40 29 88 4.54
Market Capitalization		 15 16 45 43 48 48 26 22 43 92 8.50
Book Value per Share		 $2.15 $1.43 $1.61 $1.29 $0.84 $1.07 $0.81 $0.44 ($0.02) ($0.44) ($0.07)
Tangible Book Value per Share		 $2.15 $1.43 $1.61 $1.29 $0.84 $1.07 $0.81 $0.44 ($0.02) ($0.44) ($0.07)
Total Capital		 12 8.16 17 14 9.03 14 11 6.10 -0.27 1.81 3.10
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.45 4.20
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 8.45 4.20
Net Debt		 -15 -11 -26 -19 -15 -19 -25 -18 -14 -4.57 -3.96
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.01 0.00 0.01 0.01 0.01 0.01 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.00 -3.66 -3.39 -2.61 -2.70 -2.69 -3.87 -2.47 -2.91 -3.27 -4.92
Debt-free Net Working Capital (DFNWC)		 12 7.58 22 17 12 16 21 15 11 9.75 3.24
Net Working Capital (NWC)		 12 7.58 22 17 12 16 21 15 11 9.75 3.24
Net Nonoperating Expense (NNE)		 1.24 1.12 -5.90 -0.62 1.60 -0.06 0.49 1.32 3.87 7.69 -11
Net Nonoperating Obligations (NNO)		 -15 -11 -26 -19 -15 -19 -25 -18 -14 -4.57 -3.96
Total Depreciation and Amortization (D&A)		 0.01 -0.07 -0.15 -0.20 -0.10 -0.10 -0.09 -0.10 -0.08 -0.03 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.82) $17.70 $0.01 ($0.36) ($0.50) ($0.37) ($0.36) ($0.40) ($0.52) ($0.69) $0.31
Adjusted Weighted Average Basic Shares Outstanding		 5.67M 4.49M 9.75M 11.13M 11.13M 11.25M 14.12M 15.00M 15.08M 15.01M 15.82M
Adjusted Diluted Earnings per Share		 ($0.82) $17.70 $0.01 ($0.36) ($0.50) ($0.37) ($0.36) ($0.40) ($0.52) ($0.69) $0.30
Adjusted Weighted Average Diluted Shares Outstanding		 5.67M 4.49M 10.05M 11.13M 11.13M 11.25M 14.12M 15.00M 15.08M 15.01M 16.33M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.68M 10.74M 10.75M 10.75M 13.48M 13.48M 13.97M 13.97M 0.00 15.74M 15.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.38 -3.02 -4.04 -4.57 -4.02 -4.32 -4.55 -4.63 -3.93 -3.07 -3.93
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.73 -18.06 -23.37 -32.57 16.27
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.17 -14.30 -12.06 -9.44 -17.59
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.75 -18.08 -23.39 -32.59 16.27
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -10.19 -14.32 -12.09 -9.46 -17.59
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -15.79% -13.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -15.79% -13.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

CalciMedica’s latest quarter shows a mixed picture: the company reported a quarterly net profit in Q1 2026, but that result was heavily influenced by non-operating income and does not yet reflect a sustainable turnaround in the core business. Operating performance remains loss-making, and cash continues to decline as the company funds research and development.

Revenue remains absent across the periods provided, so the company is still operating as a pre-commercial biotech with no top-line sales to offset expenses. In Q1 2026, CalciMedica posted $5.6 million in operating expenses, including $3.5 million in R&D and $2.1 million in SG&A, which produced an operating loss of $5.6 million.

Bottom-line results improved sharply in Q1 2026, with net income of $5.0 million versus a net loss of $10.8 million in Q4 2025 and a loss of $7.8 million in Q3 2025. However, the improvement appears to have come from a large $10.9 million “other income / expense, net” gain, which makes the quarter look much stronger than the underlying operating business.

Cash flow remains the bigger concern. Despite the reported profit in Q1 2026, operating cash flow was negative $4.9 million. That means the company is still burning cash from its core operations, which is typical for a clinical-stage biotech but still a key risk for investors.

Liquidity has declined materially over the past year. CalciMedica ended Q1 2026 with $8.2 million in cash and no short-term investments, down from $14.9 million in cash and investments at Q3 2025 and $25.2 million at Q1 2025. That shrinking cash balance suggests the company may need additional financing if development spending continues at the current pace.

Balance sheet leverage is also meaningful. Total liabilities were $9.7 million at Q1 2026, including $4.2 million of long-term debt. Equity remained negative at about $1.1 million, which underscores the financial fragility of the balance sheet.

Share issuance has been a recurring funding source. The cash flow statements show equity issuance in several periods, including $3.8 million in Q4 2025 and $0.8 million in Q3 2025. That helps support operations, but it also raises dilution risk for existing shareholders.

  • Q1 2026 net income turned positive at $5.0 million, a sharp improvement from the prior two quarters.
  • Investing cash flow was positive in Q1 2026 due to $1.5 million in investment maturities/sales.
  • Operating expenses were lower than Q4 2025, with total operating expenses falling to $5.6 million from $4.4 million — though still substantial.
  • There is still no revenue, so the company remains dependent on financing and pipeline progress.
  • The Q1 2026 profit was driven by non-operating items, so it may not indicate a durable earnings trend.
  • Cash and equivalents of $8.2 million provide some near-term runway, but the cushion is limited.
  • Operating cash outflow remained high at $4.9 million in Q1 2026.
  • Cash and investments fell sharply from $25.2 million in Q1 2025 to $8.2 million in Q1 2026.
  • Total liabilities exceeded total assets at Q1 2026, leaving negative equity.
  • Long-term debt of $4.2 million adds to financial risk for a company without revenue.

Overall: CalciMedica’s latest quarter shows progress on paper, but the core story is still one of cash burn, no revenue, and reliance on external capital. For retail investors, the key question is whether the company can advance its pipeline enough to justify further funding before dilution becomes a bigger issue.

07/27/26 11:23 PM ETAI Generated. May Contain Errors.

CalciMedica Financials - Frequently Asked Questions

According to the most recent income statement we have on file, CalciMedica's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

CalciMedica's net income appears to be on a downward trend, with a most recent value of -$29.56 million in 2025, falling from -$37.04 million in 2019. The previous period was -$13.70 million in 2024. See where experts think CalciMedica is headed by visiting CalciMedica's forecast page.

CalciMedica's total operating income in 2025 was -$23.12 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $23.12 million

Over the last 6 years, CalciMedica's total revenue changed from $0.00 in 2019 to $0.00 in 2025, a change of 0.0%.

CalciMedica's total liabilities were at $20.23 million at the end of 2025, a 275.8% increase from 2024, and a 65.1% increase since 2019.

In the past 6 years, CalciMedica's cash and equivalents has ranged from $1.33 million in 2022 to $33.42 million in 2020, and is currently $11.52 million as of their latest financial filing in 2025.

Over the last 6 years, CalciMedica's book value per share changed from -78.00 in 2019 to -0.44 in 2025, a change of -99.4%.


Related Companies

Financial statements for NASDAQ:CALC last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
What Elon told his top shareholders in Texas
Late last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...
Banyan Hill Publishing | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
A storm is coming
The U.S. dollar has sunk to near a four-year low, while the Bureau of Economic Analysis prepares a change to h...
Stansberry Research | Sponsoredtc pixel
Prison inmate traded $8 million the last time…
In 1998, a prison inmate known only as T9021282, Michael Matly, traded more than 8 million dollars in stocks f...
True Market Insiders | Sponsoredtc pixel
Universal Basic Income ALREADY exists
Robert Kiyosaki, author of Rich Dad Poor Dad, says you don't have to wait for Elon Musk's vision of universal ...
Freedom Financial | Sponsoredtc pixel
BofA: Digital Dollar Coming 2025-2030
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel